Blinatumomab in Pediatric B-cell Acute Lymphoblastic Leukemia (ALL) With Minimal Residual Disease (MRD)

• Immunophenotypic evidence of Cluster of Differentiation 19 (CD19) positive B precursor ALL
• Age \<18 years at the time of informed consent/assent
• B cell precursor ALL in first or later hematologic complete remission (CR) defined as less than 5% blasts in bone marrow after at least three intense chemotherapy blocks
• Persistent or recurrent MRD ≥10\^-4 in an assay with a minimum sensitivity of 10\^-5 before hematopoietic stem cell transplantation
• Bone marrow function as defined below: Absolute neutrophil count ≥1,000/μL, Platelets ≥50,000/μL (transfusion permitted), Hemoglobin level ≥9 g/dL (transfusion permitted)
• Renal and hepatic function as defined below: Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), and alkaline phosphatase (AP) \< 2 x upper limit of normal (ULN), Total bilirubin \<1.5 x ULN, Creatinine clearance ≥ 50 mL/min
• Negative HIV test, negative hepatitis B (HBsAg) and hepatitis C virus (anti-HCV) test
• Negative pregnancy test in women of childbearing potential

Exclusion Criteria:

• Presence of circulating blasts or current extramedullary involvement by ALL
• History of relevant central nervous system (CNS) pathology or current relevant CNS pathology (e.g. seizure, epilepsy, paresis, aphasia, stroke, severe brain injuries, dementia, cerebellar disease, organic brain syndrome, psychosis) with the except of CNS leukemia that is well controlled with intrathecal therapy
• Current infiltration of cerebrospinal fluid by ALL
• History of or active relevant autoimmune disease
• Systemic cancer chemotherapy within 2 weeks prior to study treatment (except for intrathecal prophylaxis)
• Radiotherapy within 4 weeks prior to study treatment
• Autologous hematopoietic stem cell transplantation (HSCT) within six weeks prior to study treatment
• Therapy with monoclonal antibodies (rituximab, alemtuzumab) within 4 weeks prior to study treatment
• Treatment with any investigational product within 4 weeks prior to study treatment
• Known hypersensitivity to immunoglobulin or to any other component of the study drug formulation
• Active malignancy other than ALL with the exception of basal cell or squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix
• Active infection, any other concurrent disease or medical condition that are deemed to interfere with the conduct of the study as judged by the investigator